Latest News | Lupin Receives USD 50 Million from Boehringer Ingelheim for Achievement of Key Milestones
Get latest articles and stories on Latest News at LatestLY. Drug major Lupin on Thursday said it has received payment of USD 50 million (around Rs 363.5 crore) from Germany-based Boehringer Ingelheim for achievement of key milestones by its novel cancer drug, a potential target therapy for patients with difficult-to-treat cancers.
New Delhi, May 27 (PTI) Drug major Lupin on Thursday said it has received payment of USD 50 million (around Rs 363.5 crore) from Germany-based Boehringer Ingelheim for achievement of key milestones by its novel cancer drug, a potential target therapy for patients with difficult-to-treat cancers.
In a regulatory filing Lupin announced "the achievement of key milestones for Lupin's MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers."
In 2019, Lupin and Boehringer Ingelheim had inked a licensing, development and commercialisation agreement for Lupin's novel oncology compound.
"As part of the agreement, Lupin has received payment of USD 50 million from Boehringer Ingelheim for achievement of key milestones," Lupin said in the regulatory filing.
Lupin said its new chemical entity research team is focused on building a pipeline of highly differentiated and innovative new chemical entities, primarily in the oncology space.
Shares of Lupin Ltd were trading 0.03 per cent lower at Rs 1,195.40 apiece on BSE.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)